Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Stanbro

Child & Adolescent Psychiatry Edmond, OK Medical Doctor

NPI 1659339224 CMS profile 255796

2000 E 15Th St Ste 400A, Edmond, OK 73013

Open in the dashboard

General payments

$1,131

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$15,470 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Peter Stanbro of Edmond, OK is reported in the CMS Open Payments database as having received $1,131 across 60 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $15,470 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35 2
2024 General $217 2
2023 General $48 2
2022 General $43 3
2021 General $292 20
2020 General $182 12
2019 General $314 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Stanbro
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Peter Stanbro were reported at $35. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Peter Stanbro Child & Adolescent Psychiatry median Middle half National median
2019 $314 $129 $42–$419 $163
2020 $182 $81 $28–$226 $114
2021 $292 $115 $31–$326 $132
2022 $43 $124 $40–$382 $149
2023 $48 $130 $45–$420 $160
2024 $217 $141 $42–$490 $164
2025 $35 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $332 16 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $204 11 payments
  3. Tris Pharma Inc $142 10 payments
  4. Noven Pharmaceuticals, Inc. $92 1 payment
  5. Neos Therapeutics, LP $58 4 payments
  6. Ironshore Pharmaceuticals Inc. $58 4 payments
  7. Janssen Pharmaceuticals, Inc $47 3 payments
  8. Allergan Inc. $42 2 payments
  9. Lundbeck LLC $37 2 payments
  10. Corium, Inc. $21 1 payment
  11. Other $98 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,101 59 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2025
  1. QELBREE Psychology $208 15 payments
  2. VYVANSE $163 9 payments
  3. Qelbree Viloxazine Hydrochloride $124 1 payment
  4. Dyanavel XR $114 8 payments
  5. Xelstrym $92 1 payment
  6. COTEMPLA XR-ODT $58 4 payments
  7. Adzenys XR-ODT $58 4 payments
  8. Jornay PM 20mg capsules (Bottle of 100) $58 4 payments
  9. VRAYLAR $42 2 payments
  10. SPRAVATO $31 2 payments
  11. Other $221 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

564

Median for Neuropsychiatry: 88

Drug cost

$26,581

Median for Neuropsychiatry: $2,689

Branded share of claims

27.1%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyvanse Lisdexamfetamine Dimesylate Brand 14 $6,754
Lisdexamfetamine Dimesylate Generic 28 $4,943
Paliperidone Er Paliperidone Brand 21 $2,277
Bromocriptine Mesylate Generic 14 $1,819
Guanfacine Hcl Er Guanfacine Hcl Brand 29 $1,677
Oxcarbazepine Generic 13 $1,546
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 48 $1,175
Carbamazepine Er Carbamazepine Brand 26 $1,076
Methylphenidate Er Methylphenidate Hcl Brand 15 $1,026
Trazodone Hcl Generic 21 $581

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $124
$124 — —
Xelstrym
  • Noven Pharmaceuticals, Inc. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record